Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval
Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB) [...]
Saved in:
| Main Author: | Heinrich Schulte-Baukloh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/17/7/351 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval: General Versus Local Anesthesia for BotulinumtoxinA Detrusor Injection
by: Heinrich Schulte-Baukloh, et al.
Published: (2024-10-01) -
Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade after Approval: A Single-Blind Study to Evaluate the Reduction in Pain in OnabotulinumtoxinA Detrusor Injection Using Different Injection Needles
by: Heinrich Schulte-Baukloh, et al.
Published: (2024-09-01) -
Correction: Shi et al. A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects. <i>Molecules</i> 2023, <i>28</i>, 1762
by: Zhenfeng Shi, et al.
Published: (2025-01-01) -
The Evolving Landscape of Childhood Histiocytosis: A Decade of Discovery and Innovation
by: Maurizio Aricò
Published: (2025-05-01) -
Correction: Shkalim Zemer et al. Pathogens Causing Pediatric Community Acquired Urinary Tract Infections and Their Increasing Antimicrobial Resistance: A Nationwide Study. <i>Pathogens</i> 2024, <i>13</i>, 201
by: Vered Shkalim Zemer, et al.
Published: (2025-02-01)